Deepak Sharma, MD
Nephrology · Milwaukee, WINPI 1366657710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Medtronic at 25.7% of the total. Reporting peaked in 2023 at $467 and has fallen 93.6% since, to $30 in 2025.
Across 21 payments — averaging $57.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$312
- AstraZeneca$256
- Bard Peripheral Vascular, Inc.$219
- Argon Medical Devices, Inc.$142
- Amgen$106
- Gilead$96
- plus $83 from 4 others
What the payments were for
- Food & beverage$1,17397%
- Education$403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 5 | $312 |
| AstraZeneca | 3 | $256 |
| Bard Peripheral Vascular, Inc. | 5 | $219 |
| Argon Medical Devices, Inc. | 1 | $142 |
| Amgen | 1 | $106 |
| Gilead | 1 | $96 |
| Covidien LP | 2 | $37 |
| Teleflex LLC | 1 | $30 |
| Lilly USA, LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLEANER$142
- ELLIPSYS VASCULAR ACCESS SYSTEM$134
- FARXIGA$125
- LOKELMA$121
- Tavneos$106
How this compares
$1,214 in reported general payments places this provider in the 70th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 23 | $121 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Milwaukee
- Kevin RegnerMilwaukee$246K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
- Anna GaddyMilwaukee$28K
- Paul HannaMilwaukee$18K
- Kevin TuckerMilwaukee$15K
- Ahmed MalikMilwaukee$15K
- Beje ThomasMilwaukee$4K
- Brahm VasudevMilwaukee$4K
- Ajjampur VidyaranyaMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.